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Abstract
Objectives This study assessed the cost-effectiveness of com-
bination treatment with gemcitabine and cisplatin compared to
treatment with gemcitabine alone for advanced biliary tract
cancer (BTC) in Japan.
Methods Amonthly transmitted Markovmodel of three states
was constructed based on the Japan BT-22 trial. Transition
probabilities among the health states were derived from a trial
conducted in Japan and converted to appropriate parameters
for our model. The associated cost components, obtained from
a receipt-based survey undertaken at the Aichi Medical
University Hospital, were those related to inpatient care, out-
patient care, and treatment for BTC. Costs for palliative care
and treatment of adverse events were obtained from the
National Health Insurance price list. We estimated cost-
effectiveness per quality-adjusted life year (QALY) at a time
horizon of 36months. An annual discount of 3 % for both cost
and outcome was considered.
Results The base case outcomes indicated that combination
therapy was less cost-effective than monotherapy when the
incremental cost-effectiveness ratio (ICER) was approximately
14 million yen per QALY gained. The deterministic sensitivity
analysis of the ICER revealed that the ICER of the base case was
robust. A probabilistic analysis conducted with 10,000-time
Monte Carlo simulations demonstrated efficacy at the willing-
ness to pay threshold of 6 million yen per QALY gained for
approximately 33 % of the population.
Conclusion In Japan, combination therapy is less cost-
effective than monotherapy for treating advanced BTC, re-
gardless of the statistical significance of the two therapies.
Useful information on the cost-effectiveness of chemotherapy
is much needed for the treatment of advanced BTC in Japan.
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Introduction
The incidence rate of biliary tract cancer (BTC) in the
Japanese population exceeds that in the US, European, and
East Asian populations. In 2015, approximately 27,000 cases
of BTC, the eighth most frequent cause of mortality from
cancer, occurred in Japan [1]. Well-known risk factors for
BTC include biliary tract diseases, such as cholelithiasis, and
inflammation of the gallbladder and biliary tract. Recently,
there has been much concern about the high incidence of
BTC in workers at printing presses because of their exposure
to 1,2-dichloropropane, which has been implicated as a pos-
sible cause of BTC.
Gemcitabine and fluoropyrimidine drugs are com-
monly used as systemic chemotherapy for advanced
BTC. In addition, a meta-analysis of 112 clinical trials
concluded that combination treatment with gemcitabine
and a platinum agent was effective for the treatment of
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BTC [2]. Furthermore, two randomized controlled trials
(RCTs ) (UK ABC-01 [ 3 ] ) d emon s t r a t e d t h a t
gemcitabine plus cisplatin (GC combination therapy)
was an effective treatment for BTC. A phase III trial
(UK ABC-02 (4)) was carried out in the UK to investi-
gate the clinical efficacy and safety of GC combination
therapy (1000 mg/m2 of gemcitabine + 25 mg/m2 of
cisplatin on days 1 and 8, repeated every 3 weeks) ver-
sus gemcitabine alone (G monotherapy) (1000 mg/m2
of gemcitabine on days 1, 8, and 15, repeated every
4 weeks) on the primary endpoints of overall survival
(OS) and progression-free survival. In the ABC-02
study [4], the treatments resulted in median OS times
of 11.7 and 8.1 months, respectively, and progression-
free survival times of 8 and 5 months, respectively.
Using the same protocol as the ABC-02 study [4], an
RCT called the BT-22 trial was conducted in Japan [5].
The results indicated that the median OS times for GC
combination therapy and G monotherapy were not sig-
nificantly different (11.2 and 7.7 months (p = 0.139),
respectively), whereas the progression-free survival
t imes were not s igni f icant ly di fferent (5 .8 and
3.7 months (p = 0.077), respectively). These findings
agreed with the results of the ABC-02 study [4]. The
updated guidelines for Japan, therefore, recommend
GC combination therapy as first-line treatment for ad-
vanced BTC.
Roth et al. [6] evaluated the cost utility of GC com-
bination therapy in the USA using the results of the
ABC-02 study [4] and concluded that GC combination
therapy was more cost-effective than G monotherapy as
per the accepted standards of willingness to pay (WTP)
in the USA (50,000 US dollars per quality-adjusted life
year (QALY) gained).
Using the results of the BT-22 trial [5], this study
assessed the cost-effectiveness of GC combination ther-
apy compared to that of G monotherapy for the treat-




A Markov model comprising three simple monthly transmit-
ted states (no progress, progress, and death) was implemented
using the results of the BT-22 trial [5] (Fig. 1). The transition
probabilities among these health states were derived from data
from the BT-22 trial [5] and converted to appropriate param-
eters for our model (see Eq. 1 and Table 1).
p ¼ 1−e−rt; ð1Þ
where pwas the probability, rwas the hazard ratio (HR), and t
was the time (months).
To calibrate and validate this model, the HR for GC
combination therapy versus G monotherapy for OS was
externally generated. This HR was then compared to
that reported in the BT-22 trial [5] and the resulting
survival curve was drawn [2].
Cost Variables
BTC-associated cost components were obtained from a
receipt-based survey of ten subjects treated at the Aichi
Medical University Hospital. The components were set
as inpatient costs, outpatient costs, medication costs for
BTC, and treatment costs for palliative care (Table 1).
An ethics approval for the survey was obtained in ad-
vance from the Medical Institute (Approval no.: 13-
034). In addition, when considering the cost of pallia-
tive care in Japan, dietary care is commonly included.
According to the National Health Insurance Price
(NHIP) list, the daily unit cost is 49,260 yen for palli-
ative care and 780 yen for meals. We, therefore, esti-
mated a total monthly cost of 1,501,200 yen by multi-
plying the summed daily unit cost by 30 days. The cost
of the chemotherapy drugs (gemcitabine and cisplatin)
and of t rea tment for adverse events (namely,
granulocyte-colony stimulating factor (G-CSF) therapy
for hematotoxicity) was calculated based on the NHIP
list (2012 revision) cost for each drug (Fig. 2).
Health Outcomes
QALY was defined as the primary health outcome. The
utility weights for the health states were devised using the
EuroQol Five Dimension (EQ-5D) questionnaire (Table 1)
and incorporated into the model. We also referred to the
Cost-Effectiveness Analysis (CEA) Registry [7],
established by the Center for the Evaluation of Value




Fig. 1 A simple and three-state Markov model on the cost-effectiveness
of the GC combination therapy versus G monotherapy
J Gastrointest Canc
Center, because the appropriate utility weights for BTC
were not available in the Japanese context.
Cost-Effectiveness Assessment
The cost-effectiveness of GC combination therapy compared
to that of G monotherapy was assessed using the incremental
cost-effectiveness ratio (ICER) at a time horizon of 36months.
An annual discount of 3 % was considered for both cost and
outcome. The health technologywas considered cost-effective
from the perspective of healthcare payers (excluding patient-
time cost), if the ICER was less than the WTP threshold of 6
million yen per QALY (converted to 500,000 yen per quality-
adjusted life month (QALM)) gained.
Sensitivity Analysis
To include uncertainty in the simulated cost-effectiveness
analysis, we conducted deterministic and probabilistic uncer-
tainty analyses using a tornado diagram andMonte Carlo sim-
ulation, respectively. The tornado diagram revealed the
parameters that influenced the base case and also demonstrat-
ed its robustness. In addition, a Bayesian approach was ap-
plied to the probabilistic analysis of the Markov model, in
which we used 10,000-time Monte Carlo simulations to
choose an efficient strategy for the aforementioned WTP
threshold of 6 million yen per QALY gained. The chosen
distribution for each of the parameters is indicated in
Table 1. In principal, continuous variables, such as the interval
scale, were assumed to follow a gamma distribution. Drug
cost was assumed to follow a triangular distribution, which
is useful as an approximate model if there are no appropriate
values available for analysis. A minimum value a (most likely
value minus 10 %), the most likely value m, and a maximum
value b (most likely value plus 10 %) were specified. The
triangular variable x was assumed to have the probability den-
sity function seen in Eq. 2:
f xð Þ ¼ 2 x−að Þ
b−að Þ m−að Þ if a < x < m
f xð Þ ¼ 2 b−xð Þ
b−að Þ m−bð Þ if m≤x < b
3
775 ð2Þ
Table 1 Parameters incorporated in the model
Parameter Distribution Mean SD N Ref.
Adverse events in G only Beta 0.688 0.07 206 [1]
Adverse events in combination Beta 0.707 0.071 206 [1]
Progress rate in combination Beta 0.1126 0.0494 41 [2]
Progress rate in G only Beta 0.1708 0.0581 42 [2]
Mortality rate in combination Beta 0.0600 0.0162 41 [2]
Mortality rate in G only Beta 0.0861 0.0433 42 [2]
Utility in no progress Gamma 0.690 0.120 - [7]
Utility in progress Gamma 0.710 0.130 - [7]
Utility in adverse events Gamma 0.678 0.120 - [7]
Monthly outpatient cost Gamma 35,148 22,402 - Receipt survey
Monthly inpatient cost Gamma 212,990 104,633 -
Parameter Distribution Minimum Most likely Maximum
Monthly palliative cost Triangular 1,330,020 1,501,200 1,625,580 NHIP 2012 rev.
Monthly cost on G-CSF agent Triangular 24,852 27,613 30,374
Monthly drug cost in G only Triangular 39,552 43,947 48,342
Monthly drug cost in comb Triangular 40,117 44,574 49,031
Regimen Day 1 Day 8 Day 15 BSA
GC 1.8 m2
Regimen Day 1 Day 8 Day 15 BSA
G 1.8 m2
Fig. 2 Regimen for treatment of advanced BTC. BSA body surface area, GC gemcitabine plus cisplatin, G gemcitabine
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Variables with binomial distributions were assumed






n2 nþ 1ð Þ ;
s
ð3Þ
where r is the event from n samples, and SD denotes
standard deviation.
Results
Model Calibration and External Validation
The survival curve is illustrated in Fig. 3. In terms of OS, the
model demonstrated no statistical significance for the HR of
0.688. In comparison, a real estimated HR of 0.69 (95 % con-
fidence interval 0.41–1.13, not significant) was retrieved from
the clinical trial [5].
Cost-Effectiveness for the Base Case
The incremental cost was approximately 3 million yen,
even though the incremental effectiveness showed a
gain of 273 QALMs. Using the relationship illustrated
in Eq. 4, we calculated the ICER to be approximately
1.1 million yen per QALM gained (converted to 13
million yen per QALY gained), indicating G monother-
apy was more cost-effective. In contrast, the base case
outcome indicated that GC combination therapy was
more effective than G monotherapy (Table 2).
3; 118; 347 yen per 2:73 QALMs ¼ 3; 118; 347 yen per 2:73 QALMs=12 months converted from months to yearsð Þ
¼ 3; 118; 347 yen per 0:2275 QALYs ¼ 13; 707; 020 yen per QALY gained ð4Þ
Deterministic and Probabilistic Sensitivity Analyses
The tornado diagram depicting the deterministic sensi-
tivity analysis of the ICER revealed that the death rate
resulting from GC combination therapy influenced the
base case. However, the robustness of the base case
was confirmed (Fig. 4).
The probabilistic analysis resulting from the 10,000-time
Monte Carlo simulations demonstrated efficacy at a WTP
threshold of less than 6 million yen per QALY gained by
approximately 33 % of the population (Fig. 5).
Discussion
We assessed the cost-effectiveness of GC combination therapy
compared to that of G monotherapy for BTC from the per-
spective of healthcare payers in Japan and concluded that G














Tine to event (month)
Modeled OS
1 3 5 7 9 111315 1719 21 232527293133 3537
G-arm
GC-arm
Fig. 3 Model calibration and external validation. Real estimated HR 0.69 (0.41–1.13), modeled HR 0.688. Real reported survival time 11.2 versus
7.7 months (GC versus G), modeled time 11.2 versus 7.7 months
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monotherapy was more cost-effective. Based on the results of
the ABC-02 trial [4], Roth et al. [6] concluded that GC com-
bination therapy was more cost-effective than G monotherapy
as per the accepted standards of WTP in the USA (50,000 US
dollars per QALY gained). The discrepancy between the re-
sults of our study (for Japan) and those of Roth’s study (for the
USA) existed because Roth’s analysis included patient-time
costs, whereas ours did not. Roth considered the perspective
of the society, whereas our study considered only the perspec-
tive of Japanese healthcare payers.
The constructedMarkovmodel was validated by confirma-
tion that the modeled survival curve and HR matched the real
estimated value. The study design of the BT-22 trial [5] was
the same as that of the ABC-02 trial [5], which used estimates
of variables for the Markov state transmission model.
Although the OS for GC combination therapy and G mono-
therapy in the BT-22 trial [5] was 11.2 and 7.7 months, re-
spectively, and that in the ABC-02 trial [4] was 11.7 and
8.5 months, respectively, the BT-22 trial was chosen for
estimating the probabilities of the Markov model because
the BT-22 trial conducted an economic evaluation in the
Japanese context, that is, it used data representative of Japan.
Even though GC combination therapy was less cost-
effective than G monotherapy in our analysis, the reliability
of extending patient survival time by approximately 3 months
by adding cisplatin to gemcitabine (compared to G monother-
apy) was significantly demonstrated in both the ABC-02 [4]
and the BT-22 [5] trials. The expanded survival timemay have
increased medical costs by requiring additional treatment for
increased side effects associated with adding cisplatin to
gemcitabine and by the requirement for longer-term palliative
care. In fact, the sensitivity analysis using the tornado diagram
revealed that the cost of palliative care influenced the cost-
effectiveness of GC combination therapy in our study.
Therefore, GC combination therapy was less cost-effective
than G monotherapy from the perspective of the healthcare
payers because the extension of survival time led to an in-
crease in medical costs.
Table 2 Base case for cost per
QALYs gained Gemcitabine plus cisplatin Gemcitabine only Incremental
Cost (yen) 15,446,575 12,328,228 3,118,347
Eff. (QALMs) 10.04 7.61 2.73
Incremental cost-effectiveness ratio (ICER) = 3 yen, 118,347/2.73 QALMs = 13,707,020 yen/QALY gained
>6,000,000/QALYs gained (not cost-effective)
QALY (M) quality-adjusted life year (month)














1,142,252  YEN per QALM gained
Fig. 4 Tornado diagram for deterministic sensitivity analysis. A
Probability of death in the GC group (0–0.083). B Probability of death
in the G group (5–0.129).C Probability of progression-free survival in the
GC group (0.045–0.119). D Probability of progression-free survival in
the G group (0.045–0.119). E Utility of progression-free survival
(0.445–0.965). F Utility of an adverse event heath state (0.443–
0.913). G Monthly discount (8.0 × 10−4–0.0043). H Cost of
palliative care (1,330,020–1,625,580 yen). J Utility of pre-
progress (0.445–0.925). K Inpatient cost (191,691–234,289 yen).
L Probability of any adverse events in the GC group (0.55–
0.826). M Probability of any adverse events in the G group
(0.58–0.846)
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The OS after GC combination therapy and G monotherapy
in the ABC-02 trial was 8.2 and 6.5 months, respectively, both
times exceeding the OS of 11.2 and 7.7 months from the BT-
22 trial. Because long-term palliative care in Japan would cost
more than that in the USA, the results of the cost-effectiveness
analysis in the Japanese context would differ from that in the
USA-based study. The guidelines for the treatment of ad-
vanced BTC in Japan recommend GC combination therapy
as first-line therapy. The fact that this therapy is more effective
and costlier should be specifically conveyed to patients before
administering the combined medication. Our study suggested
that G monotherapy is a better treatment strategy for advanced
BTC than the guideline-recommended GC combination ther-
apy by evaluation of the cost to healthcare payers in Japan.
Our study had several limitations with regard to the in-
terpretation of the results. First, the value for QALYs was
estimated by incorporating the utility weights provided by
EQ-5D and derived from the CEA Registry established by
the CEVR at the Tufts Medical Center [7]. The value was,
therefore, not specific to the Japanese population. Where
appropriate utility weights for Japanese patients with BTC
were unavailable, data regarding hepatocellular carcinoma
from the study by Roth et al. [6] were used. Nonetheless,
we ensured the applicability of the utility weights by varying
the range between the lower and upper values of the 95 %
confidence interval while conducting the deterministic sen-
sitivity analysis. Second, data on the cost variables were
obtained by referring to the medical receipts of only a few
patients from the Aichi Medical University. Additional data
in this regard would help refine the results of future studies
in this area. Third, not all patients in the real world may
benefit from the cost-effectiveness indicated by the simula-
tion results. The results of the 10,000-time Monte Carlo
simulations indicated that approximately 40 % of cases
may benefit from more cost-effective treatment.
Conclusion
GC combination therapy was predicted to be less cost-
effective than G monotherapy for treating advanced BTC in
Japan. Practitioners should consider the possible cost benefits
of GC combination therapy before patients suffering from
advanced BTC undergo chemotherapy.
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